{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T22:48:25Z","timestamp":1710456505755},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1252,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1998,8]]},"abstract":"<jats:sec><jats:title>OBJECTIVES<\/jats:title><jats:p>The commonest side\u2010effects of GH replacement therapy relate to sodium retention but its mechanism is unclear. In rats, GH inhibits renal and hepatic 11\u03b2\u2013hydroxysteroid dehydrogenase (11\u03b2\u2013HSD) activities. In man, this action might impair inactivation of cortisol to cortisone in the distal nephron thereby allowing cortisol to activate mineralocorticoid receptors. In this study, we examined the effects of GH replacement on cortisol metabolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN<\/jats:title><jats:p>A randomized double\u2010blind study comparing 6 months GH replacement with placebo in adults with GH deficiency due to pituitary or hypothalamic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS<\/jats:title><jats:p>6 men and 8 women received placebo and 8 men and 9 women received GH.<\/jats:p><\/jats:sec><jats:sec><jats:title>MEASUREMENTS<\/jats:title><jats:p>Cortisol and its metabolites were measured in overnight urine samples and in a fasting morning plasma sample at baseline and at 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Five patients withdrew from the study, 4 because of adverse effects of GH. Amongst those who completed the study, the effects of GH on cortisol metabolism differed between patients with and without ACTH deficiency. Amongst those receiving hydrocortisone replacement (<jats:italic>n<\/jats:italic>\u2003=\u200318), GH had no effect on plasma cortisol\/cortisone ratio, or urine tetrahydrocortisols\/tetrahydrocortisone ratio, but produced a substantial reduction in total urinary cortisol metabolites (from 1326\u00b1191 to 777\u00b1229 \u03bcg\/mmol creatinine; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) and an increase in urinary free cortisol\/cortisone ratio (from 0.88\u00b10.10 to 2.57\u00b10.74; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.02). By contrast, GH had none of these effects in patients with normal ACTH secretion. There were no changes in blood pressure or plasma electrolytes, aldosterone, or renin activity with GH, and no changes in any variables with placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The increase in cortisol\/cortisone ratio in urine but not in plasma, and the lack of effect on hepatic cortisol metabolites, suggests that GH inhibits both the conversion of cortisol to cortisone by renal 11\u03b2\u2013HSD2 and the conversion of cortisone to cortisol by hepatic 11\u03b2\u2013HSD1. It is unclear why this action of GH only affects patients with ACTH deficiency. The reduction in total cortisol metabolite excretion suggests that GH also affects bioavailability of hydrocortisone tablets. These observations suggest that glucocorticoid replacement therapy may need to be adjusted in hypopituitary patients who are commenced on GH replacement.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1998.00575.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:37:36Z","timestamp":1047379056000},"page":"257-263","source":"Crossref","is-referenced-by-count":25,"title":["Growth hormone replacement inhibits renal and hepatic 11\u03b2\u2013hydroxysteroid dehydrogenases in ACTH\u2010deficient patients"],"prefix":"10.1111","volume":"49","author":[{"given":"Brian R","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L","family":"Padfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"18939","DOI":"10.1016\/S0021-9258(19)47248-7","article-title":"Cloning and expression of rat cDNA encoding corticosteroid 11\u03b2\u2010dehydrogenase","volume":"264","author":"Agarwal A.K.","year":"1989","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"25959","DOI":"10.1016\/S0021-9258(18)47142-6","article-title":"NAD+\u2010dependent isoform of 11\u03b2\u2010hydroxysteroid dehydrogenase. Cloning and characterisation of cDNA from sheep kidney","volume":"269","author":"Agarwal A.K.","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(94)90176-7"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(95)03501-W"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1530041"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2471061.x"},{"key":"e_1_2_6_8_2","first-page":"632","article-title":"Cortisol and hypertension: what was not so apparent about \u2018apparent mineralocorticoid excess\u2019","volume":"122","author":"Edwards C.R.W.","year":"1993","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1989.tb01295.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00364.x"},{"key":"e_1_2_6_11_2","first-page":"52","article-title":"Application of a radioimmunoassay for angiotensin I to the physiological measurement of plasma renin activity in normal human subjects","volume":"33","author":"Haber E.","year":"1969","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-2-326"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.3.1123"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.11.4754"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000185019"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.1.151"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00288-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1430541"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128X(94)90080-9"},{"key":"e_1_2_6_20_2","first-page":"43","article-title":"Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo\u2010controlled clinical trials","volume":"1","author":"Mardh G.","year":"1994","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.00853.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1996.tb02057.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(96)00130-0"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0780049"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(95)00195-6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.2.190"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb01478.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.11.3155"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30102-6"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb01830.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(83)90062-6"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00575.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00575.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1998.00575.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T04:26:50Z","timestamp":1698467210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1998.00575.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1046\/j.1365-2265.1998.00575.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00575.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}